

Original Article



Impact of Smoke-Free Legislation on Acute Myocardial Infarction and Subtypes of Stroke Incidence in Shenzhen, China, 2012–2016: An Interrupted Time Series Analysis*

SHI Yu Lin^{1,✉}, XIONG Jing Fan^{2,✉}, LIU Li Qun¹, ZHAO Zhi Guang², WAN Xia^{1,♯}, and PENG Ji²

1. Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, China; 2. Shenzhen Center for Chronic Disease Control, Shenzhen 518001, Guangdong, China

Abstract

Objective This study assesses the impact of smoke-free legislation on the incidence rate for acute myocardial infarction (AMI) and stroke in Shenzhen.

Methods Data on ischemic ($n = 72,945$) and hemorrhagic ($n = 18,659$) stroke and AMI ($n = 17,431$) incidence covering about 12 million people in Shenzhen from 2012 to 2016 were used. Immediate and gradual changes in incidence rates were analyzed using segmented Poisson regression.

Results Following the smoke-free legislation, a 9% (95% CI: 3%–15%) immediate reduction was observed in AMI incidence, especially in men (8%, 95% CI: 1%–14%) and in those aged 65 years and older (17%, 95% CI: 9%–25%). The gradual annual benefits were observed only in hemorrhagic and ischemic stroke incidence, with a 7% (95% CI: 2%–11%) and 6% (95% CI: 4%–8%) decrease per year, respectively. This health effect extended gradually to the 50–64 age group. In addition, neither the immediate nor gradual decrease in stroke and AMI incidence rates did not show statistical significance among the 35–49 age group ($P > 0.05$).

Conclusion Smoke-free legislation was enforced well in Shenzhen, which would generate good experiences for other cities to enact and enforce smoke-free laws. This study also provided more evidence of the health benefits of smoke-free laws on stroke and AMI.

Key words: Smoke-free legislation; Second-hand smoke; Tobacco; Myocardial infarction; Stroke; Prevention

Biomed Environ Sci, 2023; 36(6): 527-536 doi: 10.3967/bes2023.064

ISSN: 0895-3988

www.besjournal.com (full text)

CN: 11-2816/Q

Copyright ©2023 by China CDC

INTRODUCTION

Tobacco use, including active smoking and exposure to secondhand smoke (SHS), is a leading cause of preventable diseases worldwide, especially for major non-communicable

diseases^[1]. Among them, the effect of SHS exposure on the public's health is substantial and extensive. Evidence indicates that the hazard of SHS exposure was nearly as large (80%–90%) as those of chronic active smoking^[2]. Given the considerable disease burden caused by SHS exposure, the WHO

*This research was supported by the CAMS Innovation Fund for Medical Sciences [CIFMS; 2016-12M-3-001] and the China Medical Board (Strengthen Capacity of Study and Application on Burden of Disease in Health Care System of China – Establishment and Development of Chinese Burden of Disease Research and Dissemination Center [15-208]).

♯Correspondence should be addressed to WAN Xia, Professor, PhD, Tel: 13621024640, E-mail: xiawan@ibms.pumc.edu.cn; PENG Ji, PhD, E-mail: pengji126@126.com

Biographical notes of the first authors: SHI Yu Lin, male, born in 1998, Master Candidate, majoring in disease burden and tobacco control; XIONG Jing Fan, female, born in 1976, Master Candidate, majoring in health education and health promotion for chronic disease.

Framework Convention on Tobacco Control (WHO FCTC) requires each member state to protect the public by adopting effective legislative measures^[3]. Until 2021, about 5.3 billion people have been covered by at least one of the six MPOWER tobacco control policy measures at the highest level of achievement^[4].

China is the largest consumer and producer of tobacco products worldwide. More than 350 million smokers smoke more than 40% of the world's cigarettes^[5] and approximately 740 million non-smokers to SHS^[6]. Among more than one million Chinese people who die of tobacco-related diseases annually, SHS exposure is responsible for nearly 230,000 deaths^[7,8]. Thus, China signed the WHO FCTC in 2003 and ratified it in 2005. However, it still does not have national smoke-free legislation that satisfies the WHO FCTC requirement^[6].

Based on the WHO FCTC regulation, more and more cities in China have successively revised or enacted smoke-free regulations since 2010. More than 20 cities have implemented smoke-free regulations to ban smoking in public places, including Shenzhen. However, the implementation of smoke-free legislation has been quantitatively evaluated only in four cities (Hong Kong, Tianjin, Qingdao, and Beijing, China), using the hospital admission or mortality data for acute myocardial infarction (AMI) and stroke from hospitals or Diseases Surveillance Points System^[9-12]. Numerous studies, mainly from North America and Europe, showed that the burden of cardiovascular and cerebrovascular diseases decreased sharply after implementing smoke-free legislation^[9-16], especially for the AMI mortality rate or admission prevalence^[10,11,17-21]. Meanwhile, only some studies focused on the subtypes of stroke, with inconsistencies among the results of some studies on stroke^[9,11,12,22-24]. In addition, the relative risks (*RRs*) for ischemic and hemorrhagic strokes caused by SHS were different, highlighting the importance of considering these separately^[25,26].

The city of Shenzhen, the first special economic zone of China, enacted local smoke-free regulations in 1998, but with several exceptions and loopholes. The regulation was amended on March 01, 2014, to meet the requirements of the WHO FCTC, with deliberations for possible exemptions to the regulation (entertainment venues and leisure service establishments were only defined as restricted smoking places and were not 100% banned until 2017), because the local government thought that it would take several years between introducing the

law and enacting it^[27]. This law banned tobacco advertising, promotion, and sponsorship and supported various institutions in actively carrying out tobacco control publicity and education. It was expected to function under the WHO FCTC framework to reduce and prevent the harm of tobacco exposure. According to a questionnaire survey conducted in Shenzhen in 2016 using random and convenience sampling methods, only 9.9% of public places smokers were found smoking^[28]. However, the implementation and the health benefit of this smoking ban need to be further evaluated. The interrupted time series (ITS) design is well-suited to address some unique characteristics of the interventions being studied and measured changes in outcomes longitudinally^[29], which also has been widely used in the assessment of tobacco control policy implementation^[9-12]. Thus, to promote the local smoke-free law implementation well, this study aimed to assess the implementation of Shenzhen's smoke-free legislation using AMI and major subtypes of stroke incidence and to estimate the health benefit of the legislation.

MATERIALS AND METHODS

Data

AMI incidence data were obtained from the Shenzhen AMI Registry System. This system was established in January 2012 and covered all Shenzhen permanent residents. Each AMI case was reported by all the secondary and tertiary hospitals in Shenzhen^[30]. The Shenzhen Center for Chronic Disease Control assessed and checked the data quality since underreporting existed in the early stage of system establishment. Therefore, we analyzed the AMI incidence data starting from May 29, 2012, when the system was stable. Stroke incidence data were obtained from the Shenzhen Stroke Registry System, established in October 2002. Its reporting procedures were similar to the AMI Registry System^[31]. Since the AMI incidence data started in 2012, this was used as the start date for the stroke data. Study subjects included in- and out-patients for AMI or stroke and ambulatory patients.

The structure of these two databases is similar. They record individual information, including a unique ID, age, sex, household type (urban or rural), dates of admission and primary diagnosis, and other relevant information. The classification of AMI and stroke was based on the International Classification

of Diseases, Tenth Version (ICD-10). We identified all cases with a principal diagnosis of stroke (hemorrhagic stroke: I60–I62, ischemic stroke: I63) or AMI (I21). The incidence of AMI and stroke was calculated based on the number of events. Recurrence within 28 days was not included in incidence calculations, and recurrence after 28 days was considered a new case^[10,11]. The sample was restricted only to the resident population aged ≥ 35 due to the low incidence of stroke and AMI among people aged < 35 .

The meteorological data on the average daily temperature and relative humidity were obtained from the Shenzhen Meteorological Bureau. The daily particulate matter with aerodynamic diameter $\leq 2.5 \mu\text{m}$ ($\text{PM}_{2.5}$) concentrations ($\mu\text{g}/\text{m}^3$) from 2015 to 2016 were obtained from the local Environmental Monitoring Center Station. $\text{PM}_{2.5}$ data from 2012 to 2014 were replaced with Tracking Air Pollution in China (TAP, <http://tapdata.org.cn/>) since the local Environmental Monitoring Center Station did not monitor $\text{PM}_{2.5}$ before 2015. This approach to tracking air pollution has been described elsewhere^[32,33]. Single-year population estimates by gender and age were obtained from the Shenzhen Bureau of Statistics.

Statistical Analysis

The crude incidence rate for all AMI, hemorrhagic stroke, and ischemic stroke was calculated as the number of annually diagnosed new cases divided by the resident population. We also calculated age-standardized incidence rates using the age structure of the Shenzhen population in 2017.

A Poisson regression model with interrupted time series was used to test the immediate and gradual changes in the crude incidence rate after the smoke-free legislation. All variables in the model were established as a time series in weeks. Multiple models were fitted by sex and age groups (35–49, 50–64, and ≥ 65 years) to evaluate the effect of the law on different subgroups. The response variable of each model was the weekly number of events for the selected diseases. An indicator variable was used to define the smoke-free legislation, with 0 given to the weeks before enforcing the law and 1 given to the weeks after enforcing it. An interaction term between legislation and weeks after the law implementation was included to estimate the change in the slope of the secular trend, and the weeks were set as 0 before enforcing the law. The age group and sex-specific resident population were

included as an offset variable with a fixed coefficient of 1 in each model. A linear predictor, adjusted the long-term time trend, was included to quantify the changes in population risk factors, treatment, and other secular trends^[10,11]. A Fourier series of sine and cosine terms was used to capture the seasonal pattern in the model. The study period for stroke and AMI was from January 01, 2012, to December 31, 2016, and from May 29, 2012, to December 31, 2016, respectively. In addition, the temperature ($^{\circ}\text{C}$), relative humidity (%), and $\text{PM}_{2.5}$ were adjusted in all models^[12,34]. The Poisson regression model is as follows:

$$\begin{aligned} \log(Y) = & \beta_0 + \beta_1 T + \beta_2 Law + \beta_3 (Law \times T) \\ & + \beta_4 \cos\left(\frac{2T\pi}{52.1775}\right) + \beta_5 \sin\left(\frac{2T\pi}{52.1775}\right) \\ & + \beta_k (Tem, Hum, PM_{2.5}) + \text{offset} \log(P), \end{aligned} \quad (1)$$

where Y denotes weekly age- and sex-specific events (AMI, hemorrhagic stroke, and ischemic stroke), P is the age- and sex-specific resident population every year, T is the time variable during the study period (week, AMI: from 1 to 240, hemorrhagic stroke and ischemic stroke: from 1 to 261), T' is the time variable (week) after law enforcement. Law represents the implementation of the smoke-free law (AMI: Law equals 0 before 93 weeks/1 after 93 weeks, stroke: Law equals 0 before 114 weeks/1 after 114 weeks). β_0 is the baseline level. β_1 represents the secular trend before law enforcement, β_2 represents the immediate effect of the ban, β_3 represents the gradual weekly effect of the ban, β_4 and β_5 represent seasonality in the model, β_k denotes the coefficient for a set of covariates. Models were fitted separately for each age group and sex.

The effect of the smoke-free legislation was reflected by the immediate and gradual change in the incidence rate, respectively. The former was quantified as $100[\exp(\beta_2)-1]$, and the latter was quantified as $100[\exp(52.1775 \times \beta_3)-1]$. In addition, the number of averted events (net post-legislation decrease) was calculated as the subtraction between the actual events and the predicted number of events without the influence of the law. All analyses were conducted in R V.4.1.0 (R Foundation for Statistical Computing, Vienna, Austria).

Ethical approval was not required as the data were deidentified, and results were presented at the group level.

RESULTS

Basic Information

Between January 01, 2012, and December 31, 2016, 72,945 incident ischemic strokes and 18,659 incident hemorrhagic strokes were identified among the resident population aged ≥ 35 years in Shenzhen. There were 17,431 cases of incident AMI from May 29, 2012, to December 31, 2016. The annual incidence rates were 398.9, 102.0, and 104.1 per 100,000 population for ischemic stroke, hemorrhagic stroke, and AMI, respectively. Overall, an annual increase in the age-standardized incidence rates for ischemic stroke and AMI was observed during the study period. A similar trend was also observed for hemorrhagic stroke. However, its standardized rates decreased in 2015 compared with previous years and then significantly increased rapidly in 2016 (Table 1). We calculated the average annual incidence rate of AMI and two stroke subtypes by age and gender during the study period (Table 2). Regardless of any disease, the incidence in men was higher than in women. In addition, the older the age group, the higher the incidence was. In particular, the incidence of ischemic stroke in the age group ≥ 65 years was about 48 times higher than in the age group 35–49 years.

Results of Incidence Regressions

For incidence rates of hemorrhagic stroke and ischemic stroke, after the enforcement of the law, the relative risk (*RR*) values on immediate effects were 0.94 [95% confidence interval (*CI*): 0.89–1.00] and 1.03 (95% *CI*: 1.00–1.07), respectively. These values meant that the immediate changes were not statistically significant (Table 3). An immediate decrease was seen in the age group ≥ 50 for hemorrhagic stroke, with statistical significance only in the age group 50–64. The immediate reduction in ischemic stroke was not observed in all subgroups. Regarding long-term effects, there was a 7% (*RR*: 0.93; 95% *CI*: 0.89–0.98) and 6% (*RR*: 0.94; 95% *CI*: 0.92–0.96) decrease in the above two diseases, respectively, with statistical significance. These annual, gradual changes were also observed in both genders with statistical significance. Regarding different age groups, the decreasing trends for hemorrhagic stroke and ischemic stroke were also more pronounced in the older age groups, with the largest reduction of 12% (*RR*: 0.88; 95% *CI*: 0.81–0.96) and 9% (*RR*: 0.91; 95% *CI*: 0.88–0.94) among the age group ≥ 65 , respectively. For the age

Table 1. Annual incidence rate (1/100,000) of AMI and stroke among the resident population aged 35 years and older in Shenzhen from 2012 to 2016

Year	Ischemic stroke incidence			Hemorrhagic stroke			AMI		
	Case, <i>n</i>	Crude annual rate (95% <i>CI</i>)	Standardized annual rate (95% <i>CI</i>)	Case, <i>n</i>	Crude annual rate (95% <i>CI</i>)	Standardized annual rate (95% <i>CI</i>)	Case, <i>n</i>	Crude annual rate (95% <i>CI</i>)	Standardized annual rate (95% <i>CI</i>)
2012	10,891	311.1 (305.3, 317.0)	281.8 (276.3, 287.4)	3,084	88.1 (85.0, 91.2)	83.6 (80.6, 86.6)	1,484*	72.7 (69.9, 75.5)	69.6 (68.8, 72.4)
2013	12,508	355.2 (349.0, 361.4)	321.0 (315.1, 326.9)	3,551	100.8 (97.5, 104.2)	95.2 (92.0, 98.5)	3,170	90.0 (86.9, 93.2)	82.5 (79.5, 85.5)
2014	14,693	412.5 (405.8, 419.1)	372.8 (366.5, 379.2)	3,716	104.3 (101.0, 107.7)	98.7 (95.5, 102.0)	3,616	101.5 (98.2, 104.8)	93.1 (89.9, 96.3)
2015	16,283	432.8 (426.2, 439.4)	391.4 (385.1, 397.7)	3,784	100.6 (97.4, 103.8)	95.5 (92.4, 98.7)	3,999	106.3 (103.0, 109.6)	97.5 (94.4, 100.7)
2016	18,570	471.5 (464.8, 478.3)	427.2 (420.7, 433.6)	4,524	114.9 (111.5, 118.2)	108.7 (105.5, 112.0)	5,162	131.1 (127.5, 134.6)	120.1 (116.7, 132.5)
Total	72,945	398.9 (392.5, 405.4)	-	18,659	102.0 (98.8, 105.3)	-	17,431	104.1 (100.8, 107.4)	-

Note. * Excluding the first 21 weeks of data.

group 35–49, the change in the annual incidence of either disease was not significant ($P > 0.05$).

After the implementation of the law, an analysis of its immediate effect showed a decrease in the AMI incidence rate, with a 9% ($RR: 0.91$; 95% $CI: 0.85–0.97$) reduction. The immediate reductions in incidence associated with the law were the highest in the age group ≥ 65 , with reductions of 17% ($RR: 0.83$; 95% $CI: 0.75–0.91$). In addition, an annual change of 6% was also observed in the AMI incidence rate. However, this difference was not statistically significant ($RR: 0.94$; 95% $CI: 0.89–1.00$), which was the same for different age groups. In different genders, an annual 8% reduction ($RR: 0.92$; 95% $CI: 0.86–0.99$) was observed only among men, as detailed in Table 3.

Protective Effect of the Law Against Incident Rates

Figures 1–3 show the observed and predicted

trends in the weekly incidence of AMI and the two subtypes of stroke among permanent residents of Shenzhen. The weekly variation incidence rate followed a seasonal pattern, with higher incidence rates in the winter and lower rates during the summer, particularly for AMI and hemorrhagic stroke (Figure 1 and Figure 2). The health effect of the smoke-free legislation can be seen in the difference in trends between the predicted incidence rates for the counterfactual scenario (red line) and the actual rate (blue line). In sum, during the whole smoke-free legislation period of 2.7 years, there were 2,422 incidents of AMI, 2,951 incidents of ischemic strokes, and 2014 incidents of hemorrhagic strokes that had been averted due to the implementation of the law. The net decrease in AMI incidence was estimated as 11.4% during the first year, reaching 16.7% by December 2016, which also was observed in all subgroups, except that the net

Table 2. Age and sex-specific incidence rates (1/100,000) of AMI and stroke in Shenzhen from 2012 to 2016

Subgroups	Ischemic stroke			Hemorrhagic stroke			AMI		
	Case, n	%	Average incidence (95% CI)	Case, n	%	Average incidence (95% CI)	Case, n	%	Average incidence (95% CI)
Age (years)									
35–49	11,236	15.4	79.2 (75.9–82.5)	6,539	35.0	46.1 (43.6–48.6)	3,551	20.3	27.2 (25.3–29.2)
50–64	24,536	33.6	787.7 (765.7–809.6)	6,945	37.2	222.9 (211.2–234.7)	5,391	30.8	188.3 (177.6–199.1)
≥ 65	37,173	51.0	3782.0 (3697.7–3866.3)	5,175	27.7	526.5 (494.5–558.5)	7,005	40.0	775.6 (736.8–814.4)
Sex									
Men	43,606	59.8	432.8 (423.7–441.9)	12,097	64.8	120.1 (115.3–124.8)	13,153	75.2	142.1 (136.9–147.3)
Women	29,339	40.2	357.4 (348.3–366.5)	6,562	35.2	79.9 (75.6–84.3)	4,345	24.8	57.6 (53.9–61.3)

Table 3. Multivariate analysis* of overall, sex-, and age-specific post-legislation effects on the incidence of AMI and two subtypes of stroke, Shenzhen

Subgroups	Ischemic stroke incidence		Hemorrhagic stroke incidence		AMI incidence	
	Immediate effect	Gradual effect per annum	Immediate effect	Gradual effect per annum	Immediate effect	Gradual effect per annum
	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
Overall	1.03 (1.00–1.07)	0.94 (0.92–0.96)	0.94 (0.89–1.00)	0.93 (0.89–0.98)	0.91 (0.85–0.97)	0.94 (0.89–1.00)
Age (years)						
35–49	1.11 (1.02–1.20)	1.00 (0.95–1.07)	1.04 (0.94–1.15)	1.00 (0.92–1.08)	1.09 (0.94–1.26)	0.99 (0.87–1.13)
50–64	1.07 (1.01–1.13)	0.95 (0.91–0.99)	0.93 (0.84–1.03)	0.91 (0.85–0.98)	0.93 (0.83–1.05)	0.91 (0.82–1.12)
≥ 65	1.00 (0.96–1.04)	0.91 (0.88–0.94)	0.85 (0.76–0.96)	0.88 (0.81–0.96)	0.83 (0.75–0.91)	0.94 (0.86–1.04)
Sex						
Men	1.02 (0.98–1.07)	0.93 (0.91–0.96)	0.95 (0.88–1.02)	0.94 (0.89–0.99)	0.92 (0.86–0.99)	0.92 (0.86–0.99)
Women	1.05 (1.00–1.11)	0.95 (0.91–0.98)	0.93 (0.84–1.03)	0.92 (0.86–0.99)	0.88 (0.77–1.01)	1.01 (0.90–1.15)

Note. * Adjusted for time trend, population, seasonality, temperature, relative humidity, and $PM_{2.5}$.

post-legislation reductions in the age group 35–49 and women were not apparent. Similar patterns were seen in hemorrhagic stroke and all of its subgroups. In the 2.7 years following the legislation, there was a net reduction of 15.1% for hemorrhagic stroke and only 6.9% for ischemic stroke.

DISCUSSION

By analyzing incidence data from two Disease Registry Systems covering about 12 million people in Shenzhen over 5 years, this study provided extensive longitudinal data and high-quality outcome assessments. Therefore, it could compare the implementation progress of smoke-free laws with other cities (such as Qingdao, Tianjin, and Beijing) in China and serve to motivate those cities without smoke-free laws to enact these laws as soon as possible. In addition, this study is the first to assess the health effects of the implementation of smoke-free legislation on major subtypes of stroke in China.

The implementation effect indicators of smoke-free legislation can be divided into short-term,

medium-term, and long-term indicators^[35]. Among them, the illegal smoking rate and SHS in non-smoking places can reflect the direct effects of enforcing the law. According to two surveys conducted in Shenzhen in 2015, the percentage of places where smokers were found was 9.9% after the policy, and the percentage of places where cigarette butts, the smell of smoke, or smokers were found was 20.6%^[28]. More than 50% of residents learned about tobacco control through TV or the Internet^[36]. 91.4% of managers and 81.0% of the public supported banning smoking in public places after the legislation, respectively^[28]. Overall, these short-term and medium-term indicators all showed that the implementation of the smoke-free legislation had given Shenzhen residents a very high sense of identity with this law. Our study provided more evidence of the health benefits of smoke-free legislation on long-term indicators. We found that as time passed, the health effects were gained for the older population and gradually extended to the younger group.

In general, the smoke-free law was implemented




Figure 1. Observed and predicted weekly AMI incidence rates (1/100,000) in Shenzhen (2012–2016).

well in Shenzhen. Following the smoke-free law, immediate reductions were observed in AMI, especially in men and in those aged 65 years and older. The gradual annual benefits were only observed in hemorrhagic stroke and ischemic stroke incidence rates after the law, with the effect extending to those aged 50 years or older. However, no matter which disease it was, the age group 35–49 was not sensitive to the health benefits of the legislation. In our opinion, the most valuable experience learned from Shenzhen is that multi-agencies should implement an effective monitoring mechanism, including the Administration Department for Market Regulation, Bureau of Transportation, Bureau of Public Security, Bureau of Education in Shenzhen, and others^[37]. The Tobacco Control Office of Shenzhen, called the administration department, charges legislation implementation. First, all the smoke-free organizations or departments referred to in the law were classified into different groups, and a designated agency

administered each group. The administration required all the agencies to perform the inspections as per their everyday activities. Random checks were implemented by the administration from time to time with live broadcasts by the media to enhance the deterrence of the law and social influence. One public place may be inspected several times until it implements the law well, which is called “wheel war” in Chinese. In addition, there was a volunteer team in Shenzhen. After the administration trained them, they also helped to inspect the policy implementation in all the public places during their daily life. Of course, Shenzhen's proximity to Hong Kong exposes its residents to many aspects of life in Hong Kong, including living in a smoke-free environment, which also helps the residents accept it and abide by the law. Therefore, we believe that other cities adjacent to Shenzhen will be impacted by this smoke-free environment in the near future.

Our results showed that the AMI incidence rates significantly decreased as immediate effects after




Figure 2. Observed and predicted weekly hemorrhagic stroke incidence rates (1/100,000) in Shenzhen (2012–2016).

the law (RR : 0.91; 95% CI : 0.85–0.97). Biological and disease mechanisms may explain this phenomenon, and even low-dose environmental tobacco exposure might result in platelet activation and aggregation. After endothelial dysfunction, the triggering of arterial vasoconstriction can increase the risk of AMI^[38,39]. Although the AMI incidence decreased of gradual effect for each age group was observed, the changes were not statistically significant, which was inconsistent with studies in New York^[40], Germany^[41], Qingdao^[11], and Tianjin^[10]. The reason may be the high proportion of the young population in Shenzhen with low AMI cases or the limited follow-up period. In addition, our study also found that the immediate effect on AMI was not significant in women. Most previous studies found that women were more sensitive to policy implementation, which meant that they gained more health effects^[42-44]. A study from the United Kingdom reported that the decrease in AMI admissions was not significant in women under 60^[19], which was similar to our results.

In our study, we further analyzed the association between the enforcement of smoke-free legislation and the incidence decrease for two stroke subtypes. Significant annual decreases in ischemic and hemorrhagic stroke incidence rates were observed right after the law. However, the immediate effect of the law was not significant, except in the age group ≥ 65 on hemorrhagic stroke. One possible explanation for this issue is that the immediate reduction in ischemic stroke incidence post-legislation could have been offset by the effect of a tobacco control project in Shenzhen. In 2010, Shenzhen initiated a smoke-free environment promotion project in five important places, including hospitals, schools, government agencies, CDC, and public transportation^[45], which may have generated a health effect for stroke. Overall, the gradual effect of the smoke-free law on stroke incidence in our study was similar to that found in Scotland^[46], Florida^[47], New York^[47], Arizona^[24], Qingdao^[11], and Beijing^[12]. Though previous studies found




Figure 3. Observed and predicted weekly ischemic stroke incidence rates (1/100,000) in Shenzhen (2012–2016).

inconsistent results in the effect of the smoke-free law on stroke, our study added further evidence to support the health effects of the law on both ischemic and hemorrhagic stroke.

In the subgroup analysis, we found evidence of stronger associations between the smoke-free law and two subtypes of stroke among older adults, which was consistent with findings from Qingdao^[11] and Beijing^[12]. In contrast, some time series studies conducted in North American and European countries and two meta-analyses found that the decrease in cardiovascular and cerebrovascular events after enforcing the law was mainly due to younger people^[14,21,46,48]. One possible explanation is that, in China, where the most concerned areas are on the legislation, most older people prefer to travel by public transportation and do physical exercises in communities or parks. Therefore, the levels of SHS exposure in these public places have dropped significantly after the legislation^[28]. In contrast, most young people prefer to go to entertainment and internet cafes during their leisure time, such as bars, dance halls, bathing centers, and other indoor venues, which had not been involved in the legislation during the study period. These places were only defined as restricted smoking places and were not 100% banned areas until 2017. Thus, further health effects evaluation should be conducted with the data after 2017. We believed that more health effects would be gained with stricter law implementation in 2017.

Some limitations of our study should be noted. First, a series of tobacco control campaigns had been conducted before the legislation was implemented, which might have affected the true health effect evaluation. Second, the sensitivity analysis was not conducted due to the limited number of weeks before the legislation. Third, some subgroups were not analyzed in other categories due to the limited data collection. More data should be collected to increase insights into different subgroup combinations. Fourth, despite adjusting for highly relevant time-varying confounders (time trends, seasonality, PM_{2.5}, others), other time-varying confounders remained, and we were unable to control them (obesity prevalence, population cholesterol levels, and others). Fifth, individual information was unavailable on covariates (smoking status, BMI) due to this study's ecological design.

CONTRIBUTORS

SHI Yu Lin completed the analysis and wrote the

first draft of the manuscript. XIONG Jing Fan helped with data collection and cleaning and contributed to the interpretation of the data. PENG Ji was in charge of the data collection and data quality improvement. WAN Xia conceived the study, supervised the analysis, and contributed to the interpretation of the data. LIU Li Qun supervised the analysis and contributed to the interpretation of the data. ZHAO Zhi Guang managed the data collection, supervised the analysis, and contributed to the interpretation of the results. All authors contributed to and have approved the final manuscript.

Received: August 5, 2022;

Accepted: December 30, 2022

REFERENCES

1. World Health Organization (WHO). WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. WHO. 2017.
2. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: Nearly as large as smoking. *Circulation*, 2005; 111, 2684–98.
3. WHO. Resolution wha 56.1. WHO framework convention on tobacco control. In: 56th World Health Assembly, 2003.
4. Burki TK. Who releases latest report on the global tobacco epidemic. *Lancet Oncol*, 2021; 22, 1217.
5. Hoffman SJ, Mammone J, Van Katwyk SR, et al. Cigarette consumption estimates for 71 countries from 1970 to 2015: Systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions. *BMJ*, 2019; 365, I2231.
6. Yang GH, Wang Y, Wu YQ, et al. The road to effective tobacco control in China. *Lancet*, 2015; 385, 1019–28.
7. Xiao L, Jiang Y, Zhang JP, et al. Secondhand smoke exposure among nonsmokers in China. *Asian Pac J Cancer Prev*, 2020; 21, 17–22.
8. Liu YL, Chen L. New medical data and leadership on tobacco control in China. *Lancet*, 2011; 377, 1218–20.
9. Thach TQ, McGhee SM, So JC, et al. The smoke-free legislation in hong kong: Its impact on mortality. *Tob Control*, 2016; 25, 685–91.
10. Xiao H, Zhang H, Wang DZ, et al. Impact of smoke-free legislation on acute myocardial infarction and stroke mortality: Tianjin, China, 2007-2015. *Tob Control*, 2020; 29, 61–7.
11. Xiao H, Qi F, Jia XR, et al. Impact of Qingdao's smoke-free legislation on hospitalizations and mortality from acute myocardial infarction and stroke: An interrupted time-series analysis. *Addiction*, 2020; 115, 1561–70.
12. Zheng YT, Wu YQ, Wang MY, et al. Impact of a comprehensive tobacco control policy package on acute myocardial infarction and stroke hospital admissions in Beijing, China: Interrupted time series study. *Tob Control*, 2021; 30, 434–42.
13. Frazer K, Callinan JE, McHugh J, et al. Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption. *Cochrane Database Syst Rev*, 2016; 2, Cd005992.
14. Tan CE, Glantz SA. Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: A meta-analysis. *Circulation*, 2012; 126,

- 2177-83.
15. Cox B, Vangronsveld J, Nawrot TS. Impact of stepwise introduction of smoke-free legislation on population rates of acute myocardial infarction deaths in flanders, belgium. *Heart*, 2014; 100, 1430-5.
 16. Konfino J, Ferrante D, Mejia R, et al. Impact on cardiovascular disease events of the implementation of argentina's national tobacco control law. *Tob Control*, 2014; 23, e6.
 17. Barr CD, Diez DM, Wang Y, et al. Comprehensive smoking bans and acute myocardial infarction among medicare enrollees in 387 US counties: 1999-2008. *Am J Epidemiol*, 2012; 176, 642-8.
 18. Ferrante D, Linetzky B, Virgolini M, et al. Reduction in hospital admissions for acute coronary syndrome after the successful implementation of 100% smoke-free legislation in argentina: A comparison with partial smoking restrictions. *Tob Control*, 2012; 21, 402-6.
 19. Sims M, Maxwell R, Bauld L, et al. Short term impact of smoke-free legislation in england: Retrospective analysis of hospital admissions for myocardial infarction. *BMJ*, 2010; 340, c2161.
 20. Galán I, Simón L, Flores V, et al. Assessing the effects of the spanish partial smoking ban on cardiovascular and respiratory diseases: Methodological issues. *BMJ Open*, 2015; 5, e008892.
 21. Mayne SL, Widome R, Carroll AJ, et al. Longitudinal associations of smoke-free policies and incident cardiovascular disease: CARDIA study. *Circulation*, 2018; 138, 557-66.
 22. Stallings-Smith S, Zeka A, Goodman P, et al. Reductions in cardiovascular, cerebrovascular, and respiratory mortality following the national irish smoking ban: Interrupted time-series analysis. *PLoS One*, 2013; 8, e62063.
 23. Humair JP, Garin N, Gerstel E, et al. Acute respiratory and cardiovascular admissions after a public smoking ban in Geneva, Switzerland. *PLoS One*, 2014; 9, e90417.
 24. Herman PM, Walsh ME. Hospital admissions for acute myocardial infarction, angina, stroke, and asthma after implementation of Arizona's comprehensive statewide smoking ban. *Am J Public Health*, 2011; 101, 491-6.
 25. Lee PN, Thornton AJ, Forey BA, et al. Environmental tobacco smoke exposure and risk of stroke in never smokers: An updated review with meta-analysis. *J Stroke Cerebrovasc Dis*, 2017; 26, 204-16.
 26. Larsson SC, Burgess S, Michaëlsson K. Smoking and stroke: A mendelian randomization study. *Ann Neurol*, 2019; 86, 468-71.
 27. Shenzhen special economic zone control smoking regulations. *J Tuberc Lung Health*, 2014; 3, 253-6. (In Chinese)
 28. Xiong JF, Xie W, Ying ZY, et al. Investigation on the implementation of Shenzhen smoking control regulations. *Chin J Health Educ*, 2016; 32, 400-3. (In Chinese)
 29. Habib N, Steyn PS, Boydell V, et al. The use of segmented regression for evaluation of an interrupted time series study involving complex intervention: The capsai project experience. *Health Serv Outcomes Res Methodol*, 2021; 21, 188-205.
 30. Lei L, Zhou HB, Peng J, et al. Analysis on epidemiological characteristics of acute myocardial infarction in shenzhen city from 2013 to 2014. *Chronic Pathematol J*, 2015; 16, 486-9. (In Chinese)
 31. Zhou HB, Chi HS, Xiong JF, et al. Analysis on the incidence and mortality of stroke in urban residents of Shenzhen. *Chin J Prev Contr Chron Non-Commun Dis*, 2008; 16, 236-8. (In Chinese)
 32. Geng GN, Xiao QY, Liu SG, et al. Tracking air pollution in China: Near real-time PM_{2.5} retrievals from multisource data fusion. *Environ Sci Technol*, 2021; 55, 12106-15.
 33. Xiao QY, Geng GN, Cheng J, et al. Evaluation of gap-filling approaches in satellite-based daily PM_{2.5} prediction models. *Atmos Environ*, 2021; 244, 117921.
 34. Madrigano J, Mittleman MA, Baccarelli A, et al. Temperature, myocardial infarction, and mortality: Effect modification by individual- and area-level characteristics. *Epidemiology*, 2013; 24, 439-46.
 35. Yang GH. Tobacco control in China. Springer. 2018, 167-70.
 36. Lin BM, Lv HZ, Guo ZQ. Residents of shajing street, Shenzhen survey on the awareness and attitude of the Shenzhen special economic zone smoking control ordinance. *Health Vocat Educ*, 2016; 34, 120-2. (In Chinese)
 37. "Shenzhen special economic zone regulations on smoking control" pressconference.2014. <http://www.sz.gov.cn/cn/xxgk/xwfy/wqhg/20140226/>.
 38. Benowitz NL. Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. *Prog Cardiovasc Dis*, 2003; 46, 91-111.
 39. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. *Prog Cardiovasc Dis*, 2003; 46, 31-8.
 40. Juster HR, Loomis BR, Hinman TM, et al. Declines in hospital admissions for acute myocardial infarction in New York State after implementation of a comprehensive smoking ban. *Am J Public Health*, 2007; 97, 2035-9.
 41. Sargent JD, Demidenko E, Malenka DJ, et al. Smoking restrictions and hospitalization for acute coronary events in germany. *Clin Res Cardiol*, 2012; 101, 227-35.
 42. Jan C, Lee M, Roa R, et al. The association of tobacco control policies and the risk of acute myocardial infarction using hospital admissions data. *PLoS One*, 2014; 9, e88784.
 43. Weaver AM, Wang Y, Rupp K, et al. Effects of smoke-free air law on acute myocardial infarction hospitalization in indianapolis and marion county, indiana. *BMC Public Health*, 2018; 18, 232.
 44. Sebríe EM, Sandoya E, Hyland A, et al. Hospital admissions for acute myocardial infarction before and after implementation of a comprehensive smoke-free policy in uruguay. *Tob Control*, 2013; 22, e16-20.
 45. Xiong JF, Liu XL, Yang YZ, et al. Passive smoking in key places in shenzhen before and after the implementation of smoke-free ban. *Chin J Prev Contr Chron Dis*, 2014; 22, 701-4. (In Chinese)
 46. Mackay DF, Haw S, Newby DE, et al. Impact of scotland's comprehensive, smoke-free legislation on stroke. *PLoS One*, 2013; 8, e62597.
 47. Loomis BR, Juster HR. Association of indoor smoke-free air laws with hospital admissions for acute myocardial infarction and stroke in three states. *J Environ Public Health*, 2012; 2012, 589018.
 48. Meyers DG, Neuberger JS, He JH. Cardiovascular effect of bans on smoking in public places: A systematic review and meta-analysis. *J Am Coll Cardiol*, 2009; 54, 1249-55.